Drug intelligence / Profile preview

Jiawei Qingluo granules

Development stage: Unknown
Lead developer: Yejishan Hospital of Wannan Medical College
Modality: Small Molecules
Administration: Oral

Overview

Jiawei Qingluo granules is a Traditional Chinese Medicine (TCM) preparation in granule form, developed with the aid of artificial intelligence technology. It is being investigated for the treatment of the active stage of rheumatoid arthritis (RA), specifically targeting the 'Dampness-heat obstruction syndrome' as defined in TCM. The drug aims to alleviate joint inflammation and improve the quality of life for patients with RA.

Other names: jiaweiqingluo加味清络颗粒

Targets

RELA (Nuclear Factor Kappa B Subunit p65)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)TP53 (Cellular Tumor Antigen p53 R175H)ESR1 (ERα)IL-6 (Interleukin 6)

Beyond the preview

Go deeper on Jiawei Qingluo granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiawei Qingluo granules.

Explore the full profile